Quotient (NASDAQ:QTNT) Stock Rating Upgraded by Zacks Investment Research

Christel Deskins

Quotient (NASDAQ:QTNT) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Saturday, Zacks.com reports. The firm currently has a $5.25 price target on the stock. Zacks Investment Research‘s price target would suggest a potential upside of 19.86% from the stock’s […]

Quotient (NASDAQ:QTNT) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Saturday, Zacks.com reports. The firm currently has a $5.25 price target on the stock. Zacks Investment Research‘s price target would suggest a potential upside of 19.86% from the stock’s current price.

According to Zacks, “Quotient Limited is a commercial-stage transfusion diagnostics company. It is focused on supplying blood-grouping consumables and developing MosaiQ, a fully automated platform for use in donor centers and patient-testing sites. Quotient Limited is headquartered in Edinburgh, Scotland and Newton, Pennsylvania. “

Several other equities research analysts have also issued reports on the company. BidaskClub lowered Quotient from a “sell” rating to a “strong sell” rating in a research note on Tuesday, September 1st. Jefferies Financial Group restated a “buy” rating and set a $13.50 price target on shares of Quotient in a research report on Wednesday, August 19th.

NASDAQ:QTNT opened at $4.38 on Friday. The firm has a market capitalization of $353.22 million, a price-to-earnings ratio of -3.11 and a beta of 2.40. Quotient has a 52-week low of $2.39 and a 52-week high of $10.38. The stock has a fifty day moving average of $6.81 and a 200 day moving average of $6.65. The company has a debt-to-equity ratio of 9.74, a quick ratio of 3.77 and a current ratio of 4.54.

Quotient (NASDAQ:QTNT) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.33) by $0.01. The business had revenue of $8.92 million for the quarter, compared to the consensus estimate of $8.50 million. Equities analysts forecast that Quotient will post -1.27 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Clearbridge Investments LLC raised its position in Quotient by 1.0% during the first quarter. Clearbridge Investments LLC now owns 3,052,476 shares of the company’s stock valued at $12,057,000 after purchasing an additional 29,055 shares in the last quarter. TimesSquare Capital Management LLC increased its holdings in shares of Quotient by 60.7% in the first quarter. TimesSquare Capital Management LLC now owns 2,922,700 shares of the company’s stock worth $11,545,000 after buying an additional 1,103,600 shares during the period. Hudson Bay Capital Management LP increased its holdings in shares of Quotient by 28.7% in the second quarter. Hudson Bay Capital Management LP now owns 1,525,000 shares of the company’s stock worth $11,285,000 after buying an additional 340,000 shares during the period. Bellevue Group AG increased its holdings in shares of Quotient by 68.3% in the second quarter. Bellevue Group AG now owns 599,154 shares of the company’s stock worth $4,434,000 after buying an additional 243,255 shares during the period. Finally, Tekla Capital Management LLC increased its holdings in shares of Quotient by 58.4% in the second quarter. Tekla Capital Management LLC now owns 411,937 shares of the company’s stock worth $3,048,000 after buying an additional 151,907 shares during the period. Institutional investors and hedge funds own 77.64% of the company’s stock.

Quotient Company Profile

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.

Featured Article: How is a buy-side analyst different from a sell-side analyst?

Get a free copy of the Zacks research report on Quotient (QTNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Quotient Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Quotient and related companies with MarketBeat.com’s FREE daily email newsletter.

Next Post

Find Cheaper Car Insurance in Just Minutes

Trying to navigate the tricky world of insurance can feel like a daunting task. To get a quote from anyone, you need to fill out forms and then compare prices and coverage from multiple providers. It’s tedious, and the complexity of the system can be overwhelming. © Soloviova Liudmyla / […]